Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV-971 in Mild to Moderate Alzheimer's Disease
NCT05908695Phase 4Recruiting
- Sponsor
- Green Valley
- Start
- Aug 2023
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sodium oligomannate in Alzheimer's disease (AD), sponsored by Green Valley. Started Aug 2023; status: recruiting.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05908695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908695.